Processa Pharmaceuticals, Inc.
PCSA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001533743
In the last 90 days, Processa Pharmaceuticals, Inc. insiders filed 5 open-market purchases and 0 sales; 12 institutions reported holding it in 13F filings for Q2 2026, worth $498.3K in total; no superinvestor holds it.
13F holders, Q4 2021
Institutional positions in Processa Pharmaceuticals, Inc. as of Dec 31, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 19
- +1 vs. Q3 2021
- Shares held
- 1.32M
- −105.7K (−7.4%) vs. Q3 2021
- Total value
- $6.47M
- −$5.75M (−47.1%) vs. Q3 2021
- New holders
- 3
- 2 more added
- Sold out
- 2
- 6 more reduced
Compare with Q3 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting PCSA on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 12 | $498.3K |
| Q1 2026 | 10 | $448.5K |
| Q4 2025 | 10 | $331.0K |
| Q3 2025 | 14 | $341.9K |
| Q2 2025 | 13 | $75.9K |
| Q1 2025 | 9 | $63.2K |
| Q4 2024 | 8 | $87.5K |
| Q3 2024 | 8 | $66.5K |
| Q2 2024 | 9 | $101.0K |
| Q1 2024 | 11 | $251.5K |
| Q4 2023 | 18 | $376.5K |
| Q3 2023 | 20 | $349.8K |
| Q2 2023 | 19 | $691.4K |
| Q1 2023 | 22 | $852.6K |
| Q4 2022 | 18 | $1.28M |
| Q3 2022 | 18 | $2.58M |
| Q2 2022 | 18 | $3.24M |
| Q1 2022 | 18 | $3.22M |
| Q4 2021 | 19 | $6.47M |
| Q3 2021 | 18 | $12.2M |
| Q2 2021 | 18 | $11.2M |
| Q1 2021 | 17 | $12.3M |
Institutions, Q4 2021
Shares, value and share of portfolio for each institution holding Processa Pharmaceuticals, Inc.; share changes are against Q3 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Vanguard Group Inc | 373,598 | $1.83M | 0.00% | −293−0.1% | Reduced |
| AIGH Capital Management LLC | 303,703 | $1.49M | 0.47% | −83,394−21.5% | Reduced |
| Solas Capital Management, LLC | 196,150 | $961.0K | 0.69% | 00.0% | Unchanged |
| Essex Investment Management Co LLC | 73,180 | $359.0K | 0.04% | −1,166−1.6% | Reduced |
| Worth Venture Partners, LLC | 70,954 | $348.0K | 0.17% | −20,014−22.0% | Reduced |
| Geode Capital Management, LLC | 64,902 | $318.0K | 0.00% | 00.0% | Unchanged |
| Verdence Capital Advisors LLC | 63,227 | $310.0K | 0.04% | −10,559−14.3% | Reduced |
| Janney Montgomery Scott LLC | 46,231 | $227.0K | 0.00% | 00.0% | Unchanged |
| State Street Corp | 41,486 | $203.0K | 0.00% | 00.0% | Unchanged |
| Coastal Bridge Advisors, LLC | 32,500 | $159.0K | 0.03% | +5,000+18.2% | Added |
| BlackRock Inc. | 30,501 | $149.0K | 0.00% | +3,477+12.9% | Added |
| Northern Trust Corp | 15,401 | $75.0K | 0.00% | 00.0% | Unchanged |
| Vectors Research Management, LLC | 4,000 | $20.0K | 0.00% | 00.0% | Unchanged |
| Allworth Financial LP | 1,700 | $8.00K | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 1,613 | $8.00K | 0.00% | +1,613 | New |
| Royal Bank of Canada | 1,000 | $5.00K | 0.00% | +1,000 | New |
| UBS Group AG | 218 | $1.00K | 0.00% | −328−60.1% | Reduced |
| Wells Fargo & Company | 63 | $0 | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 7 | $0 | 0.00% | +7 | New |
| Heritage Wealth Advisors | 0 | $0 | 0.00% | −1,000−100.0% | Sold out |
| Morgan Stanley | 0 | $0 | 0.00% | −68−100.0% | Sold out |